Current understanding of TRPM7 pharmacology and drug development for stroke

Acta Pharmacologica Sinica

Volumn 34, Issue 1, 2013, Pages 10-16

  Bae, Christine You Jin ^a   Sun, Hong Shuo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

cerebral ischemia; glutamate receptors; ion channels; neuroprotection; recombinant tissue plasminogen activator (rt PA); stroke; TRPM7

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; GLUTAMATE RECEPTOR; NEUROPROTECTIVE AGENT; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7;

CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; EXCITOTOXICITY; HUMAN; NONHUMAN; REVIEW;

ANIMALS; DRUG DISCOVERY; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; RECEPTORS, GLUTAMATE; RECOMBINANT PROTEINS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TRPM CATION CHANNELS;

EID: 84872091426     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.94     Document Type: Review

References (71)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2012. update: a report from the American Heart Association. Circulation 2012;125:e2-220.
2. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-84.
3. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-66. (Pubitemid 26295889)
4. Brown DL, Boden-Albala B, Langa KM, Lisabeth LD, Fair M, Smith MA, et al. Projected costs of ischemic stroke in the United States. Neurology 2006;67:1390-5. (Pubitemid 44632062)
5. Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke 2009;40:2068-72.
6. Saver JL. Time is brain - quantified. Stroke 2006;37:263-6. (Pubitemid 43732089)
7. Adams HP Jr, Del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American heart association/American stroke association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-711. (Pubitemid 46691097)
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
9. Marler JR, Goldstein LB. Medicine. Stroke - tPA and the clinic. Science 2003;301:1677.
10. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-54. (Pubitemid 30078164)
11. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009;32:48-55.
12. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med 1995;333:1581-7.
13. Albers GW, Olivot JM. Intravenous alteplase for ischaemic stroke. Lancet 2007;369:249-50. (Pubitemid 46136466)
14. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009;40:2438-41.
15. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA 1990;263:65-8.
16. Demaerschalk BM. Thrombolytic therapy for acute ischemic stroke: the likelihood of being helped versus harmed. Stroke 2007;38:2215-6. (Pubitemid 47457546)
17. O'Collins VE, Macleod MR, Donnan GA, Horky LL, Van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77. (Pubitemid 43358067)
18. Aarts MM, Tymianski M. TRPMs and neuronal cell death. Pflugers Arch 2005;451:243-9. (Pubitemid 41424929)
19. Aarts MM, Tymianski M. TRPM7 and ischemic CNS injury. Neuro scientist 2005;11:116-23. (Pubitemid 40388494)
20. McNulty S, Fonfria E. The role of TRPM channels in cell death. Pflugers Arch 2005;451:235-42. (Pubitemid 41424928)
21. Sun HS, Jackson MF, Martin LJ, Jansen K, Teves L, Cui H, et al. Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. Nat Neurosci 2009;12:1300-7.
22. Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, et al. A key role for TRPM7 channels in anoxic neuronal death. Cell 2003;115:863-77. (Pubitemid 38058498)
23. Xiong ZG, Zhu XM, Chu XP, Minami M, Hey J, Wei WL, et al. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 2004;118:687-98. (Pubitemid 39221729)
24. Chu XP, Papasian CJ, Wang JQ, Xiong ZG. Modulation of acid-sensing ion channels: molecular mechanisms and therapeutic potential. Int J Physiol Pathophysiol Pharmacol 2011;3:288-309.
25. Xiong ZG, Chu XP, Simon RP. Ca2+-permeable acid-sensing ion channels and ischemic brain injury. J Membr Biol 2006;209:59-68. (Pubitemid 43725456)
26. Liu HT, Tashmukhamedov BA, Inoue H, Okada Y, Sabirov RZ. Roles of two types of anion channels in glutamate release from mouse astrocytes under ischemic or osmotic stress. Glia 2006;54:343-57. (Pubitemid 44422937)
27. Oguro K, Jover T, Tanaka H, Lin Y, Kojima T, Oguro N, et al. Global ischemia-induced increases in the gap junctional proteins connexin 32. (Cx32) and Cx36 in hippocampus and enhanced vulnerability of Cx32 knock-out mice. J Neurosci 2001;21:7534-42. (Pubitemid 32904952)
28. De Pina-Benabou MH, Szostak V, Kyrozis A, Rempe D, Uziel D, Urban-Maldonado M, et al. Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. Stroke 2005;36:2232-7. (Pubitemid 41429252)
29. Thompson RJ, Zhou N, MacVicar BA. Ischemia opens neuronal gap junction hemichannels. Science 2006;312:924-7. (Pubitemid 43727327)
30. Wang H, Zhang YL, Tang XC, Feng HS, Hu G. Targeting ischemic stroke with a novel opener of ATP-sensitive potassium channels in the brain. Mol Pharmacol 2004;66:1160-8. (Pubitemid 39411056)
31. Sun HS, Feng ZP, Miki T, Seino S, French RJ. Enhanced neuronal damage after ischemic insults in mice lacking Kir6.2-containing ATPsensitive K+ channels. J Neurophysiol 2006;95:2590-601.
32. Sun HS, Feng ZP, Barber PA, Buchan AM, French RJ. Kir6.2-containing ATP-sensitive potassium channels protect cortical neurons from ischemic/anoxic injury in vitro and in vivo. Neuroscience 2007;144:1509-15. (Pubitemid 46123797)
33. Matsuda T, Arakawa N, Takuma K, Kishida Y, Kawasaki Y, Sakaue M, et al. SEA0400, a novel and selective inhibitor of the Na+-Ca2+ exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models. J Pharmacol Exp Ther 2001;298:249-56. (Pubitemid 32574534)
34. Annunziato L, Pignataro G, Di Renzo GF. Pharmacology of brain Na+/Ca2+ exchanger: from molecular biology to therapeutic perspectives. Pharmacol Rev 2004;56:633-54. (Pubitemid 39658464)
35. Pignataro G, Tortiglione A, Scorziello A, Giaccio L, Secondo A, Severino B, et al. Evidence for a protective role played by the Na+/Ca2+ exchanger in cerebral ischemia induced by middle cerebral artery occlusion in male rats. Neuropharmacology 2004;46:439-48. (Pubitemid 38223877)
36. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, et al. Newly expressed SUR1-regulated NC (Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006;12:433-40.
37. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-34.
38. MacDonald JF, Xiong ZG, Jackson MF. Paradox of Ca2+ signaling, cell death and stroke. Trends Neurosci 2006;29:75-81. (Pubitemid 43202596)
39. Margaill I, Parmentier S, Callebert J, Allix M, Boulu RG, Plotkine M. Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. J Cereb Blood Flow Metab 1996;16:107-13. (Pubitemid 26042688)
40. Steinberg GK, Panahian N, Perez-Pinzon MA, Sun GH, Modi MW, Sepinwall J. Narrow temporal therapeutic window for NMDA antagonist protection against focal cerebral ischaemia. Neurobiol Dis 1995;2:109-18.
41. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010;11:682-96.
42. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
43. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95. protein interactions. Science 2002;298:846-50. (Pubitemid 35231541)
44. Sun HS, Doucette TA, Liu Y, Fang Y, Teves L, Aarts M, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 2008;39:2544-53.
45. Zhou L, Li F, Xu HB, Luo CX, Wu HY, Zhu MM, et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med 2010;16:1439-43.
46. Besancon E, Guo S, Lok J, Tymianski M, Lo EH. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci 2008;29:268-75.
47. Wu LJ, Sweet TB, Clapham DE. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev 2010;62:381-404.
48. Monteilh-Zoller MK, Hermosura MC, Nadler MJ, Scharenberg AM, Penner R, Fleig A. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. J Gen Physiol 2003;121:49-60. (Pubitemid 36133936)
49. Yamaguchi H, Matsushita M, Nairn AC, Kuriyan J. Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. Mol Cell 2001;7:1047-57. (Pubitemid 32525751)
50. Demeuse P, Penner R, Fleig A. TRPM7 channel is regulated by magnesium nucleotides via its kinase domain. J Gen Physiol 2006;127:421-34.
51. Dorovkov MV, Ryazanov AG. Phosphorylation of annexin I by TRPM7 channel-kinase. J Biol Chem 2004;279:50643-6. (Pubitemid 40017798)
52. Clark K, Langeslag M, Van Leeuwen B, Ran L, Ryazanov AG, Figdor CG, et al. TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J 2006;25:290-301. (Pubitemid 43152850)
53. Clark K, Middelbeek J, Dorovkov MV, Figdor CG, Ryazanov AG, Lasonder E, et al. The alpha-kinases TRPM6 and TRPM7, but not eEF-2 kinase, phosphorylate the assembly domain of myosin IIA, IIB and IIC. FEBS Lett 2008;582:2993-7.
54. Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, Clapham DE. Deletion of Trpm7 disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis. Science 2008;322:756-60.
55. Ryazanova LV, Rondon LJ, Zierler S, Hu Z, Galli J, Yamaguchi TP, et al. TRPM7 is essential for Mg (2+) homeostasis in mammals. Nat Commun 2010;1:109.
56. Abed E, Moreau R. Importance of melastatin-like transient receptor potential 7 and cations (magnesium, calcium) in human osteoblastlike cell proliferation. Cell Prolif 2007;40:849-65. (Pubitemid 350135206)
57. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, et al. LTRPC7 is a Mg. ATP-regulated divalent cation channel required for cell viability. Nature 2001;411:590-5. (Pubitemid 32531406)
58. Runnels LW, Yue L, Clapham DE. TRP-PLIK, a bifunctional protein with kinase and ion channel activities. Science 2001;291:1043-7. (Pubitemid 32157413)
59. Wei WL, Sun HS, Olah ME, Sun X, Czerwinska E, Czerwinski W, et al. TRPM7 channels in hippocampal neurons detect levels of extracellular divalent cations. Proc Natl Acad Sci U S A 2007;104:16323-8. (Pubitemid 350099403)
60. Jiang J, Li M, Yue L. Potentiation of TRPM7 inward currents by protons. J Gen Physiol 2005;126:137-50. (Pubitemid 41124190)
61. Li M, Du J, Jiang J, Ratzan W, Su LT, Runnels LW, et al. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. J Biol Chem 2007;282:25817-30. (Pubitemid 47372822)
62. Lipski J, Park TI, Li D, Lee SC, Trevarton AJ, Chung KK, et al. Involvement of TRP-like channels in the acute ischemic response of hippocampal CA1 neurons in brain slices. Brain Res 2006;1077:187-99.
63. Li M, Jiang J, Yue L. Functional characterization of homo-and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol 2006;127:525-37.
64. Chen HC, Xie J, Zhang Z, Su LT, Yue L, Runnels LW. Blockade of TRPM7 channel activity and cell death by inhibitors of 5-lipoxygenase. PLoS One 2010;5:e11161.
65. Parnas M, Peters M, Dadon D, Lev S, Vertkin I, Slutsky I, et al. Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channels. Cell Calcium 2009;45:300-9.
66. Krapivinsky G, Mochida S, Krapivinsky L, Cibulsky SM, Clapham DE. The TRPM7 ion channel functions in cholinergic synaptic vesicles and affects transmitter release. Neuron 2006;52:485-96. (Pubitemid 44679819)
67. Xu H, Delling M, Jun. JC, Clapham DE. Oregano, thyme and clovederived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci 2006;9:628-35. (Pubitemid 44012260)
68. Castillo B, Porzgen P, Penner R, Horgen FD, Fleig A. Development and optimization of a high-throughput bioassay for TRPM7 ion channel inhibitors. J Biomol Screen 2010;15:498-507.
69. Zheng C, Han L, Yap CW, Xie B, Chen Y. Progress and problems in the exploration of therapeutic targets. Drug Discov Today 2006;11:412-20.
70. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-50.
71. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8.